Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781611 · ClinicalTrials.gov registry record · NA
Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
A NA study, sponsored by Oklahoma Medical Research Foundation.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT01781611: Clinical Trial NA study, sponsored by Oklahoma Medical Research Foundation.
NCT01781611 is a NA study that was terminated before completion, run by Oklahoma Medical Research Foundation. The registered enrollment target is 18 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01781611, a NA study, was terminated before completion, sponsored by Oklahoma Medical Research Foundation.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice with lupus. The investigators are interested in investigating the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on biomarkers of disease activity.
Primary Outcome
This is a landmark measure of percentage of patients who meet response criteria. To meet the BICLA response measure a patient must, compared to baseline, have a decrease in all moderate or severe scores on the British Isles Lupus Assessment Group (BILAG) index by at least one severity grade (Severe disease (BILAG A score) must drop to at least moderate (B or better) and B must drop to at least mild (C or not present). Also, there must be no increase in any other BILAG organ scores, no increase i
Interventions
- DRUG extended release dipyridamole 200mg/aspirin 25mg
- DRUG 81mg aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-11 |
| Phase | NA |
Why NCT01781611 stopped before completion
NCT01781611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which extended release dipyridamole 200mg/aspirin 25mg is the first listed.
NCT01781611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01781611 about?
NCT01781611 is a clinical study titled "Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)". Dipyridamole, a medication extensively used in combination with aspirin for stroke prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of lupus-related pathology in mice w...
What is the current status of trial NCT01781611?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2013-02. Estimated completion is 2017-11.
What interventions are being tested in trial NCT01781611?
The interventions under investigation include: extended release dipyridamole 200mg/aspirin 25mg (DRUG), 81mg aspirin (DRUG).
Who is sponsoring clinical trial NCT01781611?
This trial is sponsored by Oklahoma Medical Research Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01781611's enrollment target sits among peer trials
18 1863rd of 2000 higher than 130 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia